<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01690572</url>
  </required_header>
  <id_info>
    <org_study_id>DEBT</org_study_id>
    <nct_id>NCT01690572</nct_id>
  </id_info>
  <brief_title>Drug Eluting Balloon for Prevention of Constrictive Remodeling</brief_title>
  <official_title>Drug Coated Balloon (DCB) for the Prevention of Constrictive Remodeling and Restenosis in Small Vessel Coronary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. med. Christoph Hehrlein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Herz-Zentrums Bad Krozingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Earlier studies indicated that Percutaneous coronary intervention (PCI) may be problematic in
      diffuse small vessel disease especially of diabetic patients. High restenosis rates after
      balloon only procedures in small vessels occur due to negative constrictive vessel remodeling
      if DES (drug eluting stents) are not used and prolonged anti-platelet therapy is not
      indicated. The main hypothesis of the trial is that in analogy to DCB success in peripheral
      arterial disease (PAD), cellular toxicity of the drug paclitaxel eluting from a IN.PACT
      FalconTM DCB will prevent constrictive remodelling of small coronary vessel segments after
      dilatation. The IN.PACT FalconTM DCB is compared with plain old balloon angioplasty (POBA)
      using a Sprinter LegendTM balloon in small vessel coronary artery disease. A constrictive
      remodelling process will be measured by optical coherence tomography (OCT) at 9 months median
      F/U. This pilot trial is planned to be randomized 1:1 for DCB against POBA therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment was not sufficient.
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MACE-rate</measure>
    <time_frame>12 months after initial treatment</time_frame>
    <description>combined end-point: death, myocardial infarction and revascularisation of the target lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OCT-measurement</measure>
    <time_frame>during follow-up, after 9 months</time_frame>
    <description>each symptomatic patient will be examined using optical coherence tomography to detect, if the symptoms are caused by a narrowing at the target lesion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Paclitaxel coated balloon catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel coated balloon catheter &quot;IN.PACT Falcon&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>uncoated balloon catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>uncoated balloon catheter &quot;sprinter legend&quot;</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paclitaxel coated balloon catheter</intervention_name>
    <description>Dilatation of the target lesion</description>
    <arm_group_label>Paclitaxel coated balloon catheter</arm_group_label>
    <other_name>IN.PACT Falcon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>uncoated balloon catheter &quot;sprinter legend&quot;</intervention_name>
    <description>Dilatation of the target lesion</description>
    <arm_group_label>uncoated balloon catheter</arm_group_label>
    <other_name>sprinter legend</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  at least one target lesion with a stenosis severity ≥ 50% in one coronary segment with
             a diameter ≤ 2.5 mm

          -  age &gt; 18 years

          -  weight &gt; 45 kg

          -  patient suitable for balloon dilatation and not suitable for elective implantation of
             a drug eluting stent

          -  insulin-dependent or non-insulin-dependent diabetes mellitus

          -  length of lesion ≥ 15 mm

        Exclusion Criteria:

          -  Life expectancy &lt; 12 months

          -  In-Stent restenosis

          -  planned coronary bypass or heart valve OP

          -  ST elevation myocardial infarction within the last 72 hours

          -  cardiogenic shock

          -  renal impairment or liver dysfunction (creatinine &gt; 2.0 mg/dl, AST/ALT &gt; 3x of normal
             value

          -  incompliance

          -  pregnant or breastfeeding women or women who like to be pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Hehrlein, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology and Angiology I, Heart Center, Freiburg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology and Angiology I, Heart Center,</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2012</study_first_submitted>
  <study_first_submitted_qc>September 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herz-Zentrums Bad Krozingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Christoph Hehrlein</investigator_full_name>
    <investigator_title>Professor Dr. med.</investigator_title>
  </responsible_party>
  <keyword>drug eluting balloon</keyword>
  <keyword>constrictive remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

